- QQ3 2025 for Acro Biomedical shows a continued loss trajectory with no disclosed revenue in the reported quarter, underscoring the company’s cash burn and liquidity fragility. A single-quarter operating expense run rate of 115,099 USD (SG&A/operating expenses) coincides with an EBITDA of -115,099 USD and a net income of -117,809 USD, implying limited near-term profitability or revenue recognition in the period. Diluted EPS stood at -0.002 on 60.04 million weighted-average shares.
- The balance sheet and cash-flow signals are concerning. Current, quick, and cash ratios are all reported at 0.00989, indicating an acute liquidity squeeze and dependence on external financing. Interest coverage is deeply negative (-42.47x), further highlighting near-term solvency risk if funding environments tighten. Management commentary is not present in the supplied transcript data, limiting the ability to corroborate drivers or planned mitigations in QQ3.
- Relative to a peer group of select biotech/growth-oriented companies shown in the dataset, Acro Biomedical’s metrics contrast sharply with firms that exhibit positive profitability and stronger liquidity signals. This positions ACBM as a highly speculative, pre-revenue or early-stage incubator with substantial execution risk, contingent on successful commercialization milestones or transformative partnerships. Investors should weigh potential upside from potential cordycepin/cordyceps-related revenue streams against the close liquidity runway and lack of visible top-line growth in QQ3 2025.